Academic literature on the topic 'Scale Free CORDIC'

Introduction: In Orthodontics separator elastics are used to create space for inserting the bands. This causes pain. Phytotherapy has been promising as a therapy. Objective. This double blind randomized clinical trial evaluated the level of pain due to the use of elastic separator (SE) after intraoral topical administration of Cordia verbenacea gel (CV). Methods. 50 volunteers received the SE on the mesial and distal surfaces of the maxillary first molars. In a blinded manner, 0.5 g of the gel was used in one hemi-arch, and placebo in the other hemi-arch on the free gingival margin of the first molar, every 8 hours, for 3 days. Pain was measured on a visual analog scale (VAS), before insertion of the SE (t0), immediately after (t1) and every hour after the following applications. Sensory analysis of the was performed for effects of taste and burning. Wilcoxon (comparison between sides) and Friedman and Nemenyi tests were performed for comparisons between times (α=0.05). Results. The pain was lower on the side that received the phytotherapeutic gel, from the first application until before the removal of the elastic (p 0.05). As regards the burning sensation, the experimental side had higher scores and 20% of the subjects considered the CV gel had an unpleasant taste. It was concluded that the use of the intrabucal topic of CV has an analgesic potential for pain resulting from the insertion of SE.

Abstract Background: Partial breast irradiation (PBI) is an established option for selected patients with early stage breast cancer. The optimal technique, target volume and dose/fractionation for PBI has yet to be defined. The most studied regimen in North America (38.5 Gy in 10 fractions twice daily) has been associated with cosmetic deterioration. We hypothesized that condensing treatment and reducing the total administered dose could improve the therapeutic ratio in luminal breast cancer and DCIS based on emerging evidence that breast cancer is more sensitive than surrounding normal tissues to high dose fractions. Herein, we report cosmetic, tolerability, disease control, and patient reported outcomes of a novel ultra-accelerated PBI regimen. Methods: We conducted a single arm, three cohort trial of photon, proton, and brachytherapy PBI. Technique was selected at physician and patient discretion. Eligible women were age ≥ 50 years with estrogen receptor positive (ER+), sentinel lymph node negative invasive or in-situ breast cancer measuring ≤ 2.5 cm. The regimen was designed to have comparable biologically equivalent effect as 40 Gy in 15 fractions, assuming an α/β ratio of 3.5. Intracavitary brachytherapy target volume was lumpectomy cavity plus 1 cm and prescribed 21 Gy in 3 fractions. Photon and proton target volumes were post-operative tumor bed plus 1 cm and a 3 mm setup uncertainty margin, prescribed 21.9 Gy (RBE) in 3 fractions, and delivered with image guidance. The primary outcome was the percentage difference in patients with adverse cosmesis (defined as fair or poor cosmesis) at 3 years compared to baseline pre-PBI, as assessed by trained nurses using the 4-point Harvard breast cosmesis scale. Patients also completed quality of life surveys and self-reported cosmesis using the 4-point scale. Locoregional and distant recurrence-free survival was determined using the Kaplan-Meier method. Adverse events were assessed using CTCAE, v 4.0. Results: Between 2015 and 2017, 163 patients were treated: photons in 58, protons in 48, and brachytherapy in 57. Median patient age was 66 years. 129 (79%) patients had invasive breast cancer (all ER+) and 34 (21%) had DCIS (83% ER+). Median tumor size was 1.1 cm. Grade was 2-3 in 102 (63%). The median mean heart/ipsilateral lung doses were photons 0.1/1.6 Gy, protons <0.001/0.1 Gy, and brachytherapy 0.5/0.9 Gy. Median follow-up was 4.1 years (IQR 3.9-5.0). The proportion of patients with adverse cosmesis (by RN assessment) was 14.3% at baseline and 3.8% at 3 years, with four patients (1 photon, 1 proton, 2 brachytherapy) experiencing cosmetic deterioration at 3 years from baseline. The proportion with adverse cosmesis by self-report at 3 years was 2.4%, with three patients (1 photon, 1 proton, 1 brachytherapy) reporting cosmetic deterioration. Four patients developed locoregional recurrence (1 photons, 2 protons, 1 brachytherapy); three were local only and one was local and distant. 4-year locoregional recurrence and distant metastasis-free survival were 97.9% and 97.4%, respectively. There were 2 treatment related ≥ grade 2 late events (grade 2 fibrosis and grade 2 seroma, both brachytherapy associated), and no evidence of deterioration in patient-reported pain, fatigue, breast related or overall quality of life, as assessed by the patient reported outcomes version of the CTCAE, 10-point linear analog scales, and the breast cancer treatment outcomes scale. Conclusions: Ultra-accelerated 3-fraction PBI exquisitely spared normal tissues and was associated with favorable cosmetic outcomes, disease control, and excellent long-term tolerability. This ‘precision-radiotherapy’ approach may optimize the therapeutic ratio over more aggressive radiotherapy options as well as radiotherapy omission, particularly in patients with long life expectancies. Citation Format: Robert Mutter, Tina Hieken, Todd DeWees, Arslan Afzal, Stephanie Kenison, Laura Vallow, Christopher Deufel, Nicholas Remmes, Kathryn Ruddy, Judy Boughey, Keith Furutani, Amy Degnim, James Jakub, Tamara Vern-Gross, Dean Shumway, William Wong, Samir Patel, Lisa McGee, Minetta Liu, Carlos Vargas, Daniel Visscher, Bradley Stish, Deanna Pafundi, Mark Waddle, Michael Golafshar, Michele Halyard, Kimberly Corbin, Sean Park. Ultra-accelerated photon, proton, and brachytherapy partial breast irradiation: Primary results of the Mayo 3-fraction trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD7-03.

AbstractIn this article, a low-complexity VLSI architecture based on a radix-4 hyperbolic COordinate Rotion DIgital Computer (CORDIC) is proposed to compute the $$N{{\rm th}}$$ N th root and $$N{{\rm th}}$$ N th power of a fixed-point number. The most recent techniques use the radix-2 CORDIC algorithm to compute the root and power. The high computation latency of radix-2 CORDIC is the primary concern for the designers. $$N{{\rm th}}$$ N th root and $$N{{\rm th}}$$ N th power computations are divided into three phases, and each phase is performed by a different class of the proposed modified radix-4 CORDIC algorithms in the proposed architecture. Although radix-4 CORDIC can converge faster with fewer recurrences, it demands more hardware resources and computational steps due to its intricate angle selection logic and variable scale factor. We have employed the modified radix-4 hyperbolic vectoring (R4HV) CORDIC to compute logarithms, radix-4 linear vectoring (R4LV) to perform division, and the modified scaling-free radix-4 hyperbolic rotation (R4HR) CORDIC to compute exponential. The criteria to select the amount of rotation in R4HV CORDIC is complicated and depends on the coordinates $$X^j$$ X j and $$Y^j$$ Y j of the rotating vector. In the proposed modified R4HV CORDIC, we have derived the simple selection criteria based on the fact that the inputs to R4HV CORDIC are related. The proposed criteria only depend on the coordinate $$Y^j$$ Y j that reduces the hardware complexity of the R4HV CORDIC. The R4HR CORDIC shows the complex scale factor, and compensation of such scale factor necessitates the complex hardware. The complexity of R4HR CORDIC is reduced by pre-computing the scale factor for initial iterations and by employing scaling-free rotations for later iterations. Quantitative hardware analysis suggests better hardware utilization than the recent approaches. The proposed architecture is implemented on a Virtex-6 FPGA, and FPGA implementation demonstrates $$19\%$$ 19 % less hardware utilization with better error performance than the approach with the radix-2 CORDIC algorithm.